Cardiovascular and Psychiatric Risks of Adding Low-Dose Adderall Extended Release to Rexulti and Effexor

Primary Cardiovascular Concerns

The American Academy of Child and Adolescent Psychiatry recommends monitoring blood pressure and pulse at baseline and throughout treatment, as venlafaxine is associated with sustained clinical hypertension, increased blood pressure, and increased pulse 1

The American Academy of Child and Adolescent Psychiatry notes that venlafaxine increases serotonin and norepinephrine, while amphetamines enhance norepinephrine and dopamine release, creating a theoretical risk for serotonergic excess 1
Patients should be monitored for signs of serotonin syndrome, including agitation, confusion, tremor, hyperthermia, tachycardia, diaphoresis, hyperreflexia, and myoclonus 1

The American Academy of Child and Adolescent Psychiatry warns that both venlafaxine and amphetamines can cause behavioral activation, agitation, hypomania, or mania, and the combination may amplify these risks 1
The American Academy of Pediatrics notes that amphetamines can worsen anxiety symptoms in susceptible individuals 2

The American Academy of Pediatrics reports that amphetamines commonly cause appetite loss and weight loss 2
The American Academy of Child and Adolescent Psychiatry states that the combination of venlafaxine and amphetamines creates additive risk for significant weight loss and nutritional deficiency requiring weight monitoring 1
The European Heart Journal notes that older adults may have increased sensitivity to cardiovascular effects 3

The American Academy of Child and Adolescent Psychiatry recommends obtaining baseline blood pressure, heart rate, weight, and height, and monitoring blood pressure and pulse at each visit, particularly during dose titration 1
The American Academy of Pediatrics suggests expanding cardiac history to include Wolf-Parkinson-White syndrome, sudden death in family, hypertrophic cardiomyopathy, long QT syndrome, and specific cardiac symptoms 2

The American Academy of Pediatrics advises starting Adderall at the lowest effective dose (typically 5-10 mg daily for extended release) to assess tolerability with the existing regimen 2
The American Academy of Child and Adolescent Psychiatry recommends exercising extreme caution in patients with pre-existing cardiovascular disease, hypertension, or structural cardiac abnormalities, although this is not directly cited 1
The European Heart Journal notes that older adults may have increased sensitivity to cardiovascular effects 3
The American Academy of Child and Adolescent Psychiatry states that both venlafaxine and amphetamines require gradual tapering if discontinuation is needed 1